OncoMatch/Clinical Trials/NCT04305548

Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

Is NCT04305548 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Trabectedin for mesenchymal chondrosarcoma.

Phase 2RecruitingItalian Sarcoma GroupNCT04305548Data as of Jun 2026Location: Italy

Treatment: Trabectedin — Prospective, uncontrolled, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic)

Check if I qualify

Extracted eligibility criteria

Treatments studied

Chemotherapy

Trabectedin

Biomarker criteria

Required: HEY1 HEY1-NCOA2 fusion

documented presence of HEY1-NCOA2 fusion

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages ≥ 16

Prior therapy

Max 3 prior lines

Min 1 prior line

Must have received: anthracycline — advanced phase

pre-treated with at least one prior chemotherapy treatment containing anthracyclines for the advanced phase of disease and with a maximum of 3 lines

Cannot have received: radiation therapy

Previous treatment with radiation therapy within 14 days of first day of study drug dosing

Cannot have received: radiation therapy

Previous radiotherapy to 25% of the bone marrow

Lab requirements

Blood counts

Adequate bone marrow function

Kidney function

Adequate organ function

Liver function

Adequate organ function

Cardiac function

Cardiac ejection fraction ≥50% as measured by echocardiogram; Grade III/IV cardiac problems as defined by the New York Heart Association Criteria [excluded]

Adequate bone marrow function; Adequate organ function; Cardiac ejection fraction ≥50% as measured by echocardiogram; Grade III/IV cardiac problems as defined by the New York Heart Association Criteria [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT04305548 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior radiation therapy, radiation therapy disqualifies patients from enrollment.

Does this trial require HEY1?

Yes, HEY1 HEY1-NCOA2 fusion is a required biomarker for enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify